ScholarIQanswers from OpenAlex & ORCID
Matthew H. Kulke
ResearcherPublications, citations & collaboration network
Matthew H. Kulke is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Matthew H. Kulke have?
ScholarIQindexed works
Matthew H. Kulke has 420 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Matthew H. Kulke have?
ScholarIQcitation count
Matthew H. Kulke has 28,516 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Matthew H. Kulke?
ScholarIQh-index
Matthew H. Kulke has an h-index of 83 in OpenAlex.
What is the i10-index of Matthew H. Kulke?
ScholarIQi10-index
Matthew H. Kulke has an i10-index of 214 in OpenAlex.
What is the ORCID of Matthew H. Kulke?
ScholarIQorcid
The ORCID for Matthew H. Kulke is on the source record.
What is the OpenAlex record for Matthew H. Kulke?
ScholarIQopenalex
The OpenAlex for Matthew H. Kulke is on the source record.
What are the most-cited papers on Matthew H. Kulke?
ScholarIQmost cited works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Pamela L. Kunz, Diane Reidy‐Lagunes, Lowell Anthony, Erin M. Bertino, Kari Brendtro, Jennifer A. Chan, Herbert Chen, Robert T. Jensen, Michelle Kang Kim, David S. Klimstra, Matthew H. Kulke, Eric H. Liu, David C. Metz, Alexandria T. Phan, Rebecca S. Sippel, Jonathan Strosberg, James C. Yao
NANETS Treatment Guidelines
Matthew H. Kulke, Lowell Anthony, David Bushnell, Wouter W. de Herder, Stanley J. Goldsmith, David S. Klimstra, Stephen J. Marx, Janice L. Pasieka, Rodney F. Pommier, James C. Yao, Robert T. Jensen